The primary objective of this pilot trial is to determine whether inpatients presenting to the Emergency Department (ED) with symptoms suggestive of Acute Heart Failure (AHF), who receive supplemental oxygen adjusted at either a high (SpO2 range ≥96%) or low (SpO2 range 90-92%) oxygen saturation level, leads to greater reduction in N-terminal-proBNP (NT-proBNP) at 72 hours.
Patients will be randomized to either a high (SpO2 range ≥96%) or low (SpO2 range 90-92%) oxygen after informed consent.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
50
University of Alberta Hospital / Mazankowski Alberta Heart Institute
Edmonton, Alberta, Canada
Change in NT-proBNP from baseline to 72 hours
Time frame: 72 hours
Change in dyspnea using the visual analog scale (VAS) from baseline to 72 hours
Time frame: 72 hours
Change in global symptoms using the Patient Global Assessment scale (PGA) from baseline to 72 hours
Time frame: 72 hours
Change in Peak Expiratory Flow Rate (PEFR) from baseline to 72 hours
Time frame: 72 hours
Number of worsening heart failure (WHF) events
Time frame: 7 days
30-day clinical events
All cause mortality, HF readmission, days alive and out of hospital
Time frame: 30 days
Average z-score from the combination of these outcomes: PGA, NT-proBNP, 7-day WHF, 30-day mortality and re-hospitalization
Time frame: 30 days
Hochberg endpoint (combination of NT-proBNP and PGA)
Time frame: 72 hours
Diuretic response (weight loss up to 72 hours and urine volume up to 24 hours)
Time frame: 72 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.